Caffeine is a trimethylxanthine stimulant that acts as an adenosine receptor antagonist in the central nervous system, promoting alertness and reducing fatigue. It is one of the most widely consumed psychoactive substances globally, found naturally in coffee, tea, and other beverages, and is well-established as an ergogenic aid that enhances physical performance, cognitive function, and endurance across various athletic and cognitive tasks.

Overview

Caffeine (1,3,7-trimethylxanthine) is a methylxanthine alkaloid naturally present in over 60 plant species, including Coffea arabica (coffee), Camellia sinensis (tea), and Theobroma cacao (cocoa). Its primary mechanism of action involves competitive antagonism of adenosine receptors, particularly the A1 and A2A subtypes, which blocks the sleep-promoting effects of adenosine and increases neuronal firing, norepinephrine release, and dopaminergic signaling.

Caffeine is rapidly absorbed from the gastrointestinal tract, reaching peak plasma concentrations within 30 to 60 minutes of ingestion. It is metabolized primarily in the liver by the cytochrome P450 enzyme CYP1A2 into paraxanthine, theobromine, and theophylline. The half-life of caffeine varies considerably between individuals, typically ranging from 3 to 7 hours, and is influenced by genetics, age, liver function, and concurrent medications. Regular consumption leads to physiological tolerance, and abrupt cessation can produce withdrawal symptoms including headache, fatigue, and irritability.

Beyond its well-established cognitive and ergogenic effects, caffeine has been studied for its potential protective effects against Parkinson's disease, Alzheimer's disease, and certain cancers. It is also a common ingredient in analgesic formulations, where it enhances the efficacy of acetaminophen and aspirin. The U.S. Food and Drug Administration generally recognizes caffeine as safe (GRAS) at moderate intake levels of up to 400 mg per day for healthy adults.

Mechanism of Action

Adenosine Receptor Antagonism

Caffeine (1,3,7-trimethylxanthine) is a non-selective competitive antagonist at adenosine A1 and A2A receptors, the two subtypes most relevant to its psychostimulant and ergogenic effects. Adenosine accumulates extracellularly during wakefulness as a byproduct of ATP metabolism and neuronal activity, promoting sleep via A1-mediated inhibition of wake-promoting basal forebrain cholinergic neurons and A2A-mediated activation of sleep-promoting ventrolateral preoptic (VLPO) neurons. Caffeine blocks these receptors (Ki ~ 10-40 microM), preventing adenosine's somnogenic signaling and maintaining cortical arousal (PMID: 20164566).

Downstream Dopaminergic & cAMP Effects

A2A receptors form heteromeric complexes with dopamine D2 receptors in the striatum, where A2A activation allosterically reduces D2 receptor affinity for dopamine. Caffeine's A2A blockade disinhibits D2 signaling, enhancing dopaminergic neurotransmission in the nucleus accumbens and dorsal striatum — contributing to its reinforcing properties and psychomotor stimulation. Additionally, A1 receptor blockade prevents Gi-mediated inhibition of adenylyl cyclase, increasing cAMP levels and PKA-mediated phosphorylation of DARPP-32 and CREB in cortical and striatal neurons (PMID: 18088379).

Phosphodiesterase Inhibition & Calcium Mobilization

At higher concentrations (>100 microM), caffeine inhibits cyclic nucleotide phosphodiesterases (PDEs), prolonging cAMP and cGMP signaling. It also sensitizes ryanodine receptors (RyR) on the sarcoplasmic reticulum, enhancing calcium-induced calcium release in skeletal muscle. This increases peak force production and reduces the perception of effort during sustained contractions, contributing to its ergogenic effects in endurance and strength performance (PMID: 20378318).

Metabolic & Lipolytic Effects

Caffeine increases lipolysis through PKA-mediated phosphorylation of hormone-sensitive lipase (HSL) and perilipin in adipocytes, elevating circulating free fatty acids and glycerol. It also increases resting metabolic rate by 3-11% through sympathetic nervous system activation via central A1 blockade and peripheral catecholamine release (PMID: 7486839).

Reconstitution Calculator

Research

Safety Profile

Common Side Effects

• Insomnia and sleep disturbances, particularly when consumed within 6 hours of bedtime due to caffeine's average half-life of 3-7 hours (varies by individual metabolism)
• Anxiety, nervousness, jitteriness, and restlessness, especially at doses exceeding 200 mg or in caffeine-sensitive individuals
• Gastrointestinal effects including acid reflux, stomach irritation, nausea, and diarrhea; caffeine stimulates gastric acid secretion
• Increased heart rate (tachycardia) and palpitations
• Elevated blood pressure, typically transient (5-10 mmHg increase)
• Frequent urination due to mild diuretic effect
• Headache, both as a side effect of consumption and as a withdrawal symptom

Serious Adverse Effects

• Caffeine toxicity can occur at doses above 1,200 mg in a short period, with symptoms including seizures, cardiac arrhythmias, rhabdomyolysis, and in extreme cases, death. Lethal dose is estimated at 10-14 grams for adults
• Chronic high intake (>600 mg/day) is associated with chronic insomnia, anxiety disorders, gastrointestinal disorders, and potential bone density reduction
• Physical dependence develops with regular use; withdrawal symptoms (headache, fatigue, irritability, depressed mood, difficulty concentrating) begin 12-24 hours after last dose and peak at 20-51 hours
• Caffeine-induced anxiety disorder and caffeine-induced sleep disorder are recognized diagnoses in the DSM-5

Contraindications

• Individuals with uncontrolled anxiety disorders, panic disorder, or insomnia should limit or avoid caffeine
• Those with cardiac arrhythmias (particularly atrial fibrillation, SVT) or uncontrolled hypertension should restrict intake
• Individuals with gastroesophageal reflux disease (GERD) or active peptic ulcers
• Seizure disorders may be exacerbated by high caffeine intake

Drug Interactions

• CYP1A2 inhibitors (fluvoxamine, ciprofloxacin, oral contraceptives, cimetidine) significantly slow caffeine metabolism, increasing plasma levels and risk of toxicity
• May reduce the efficacy of sedative and anxiolytic medications (benzodiazepines, zolpidem)
• Additive effects with other stimulants (ephedrine, amphetamines, pseudoephedrine)
• May reduce absorption of iron and calcium supplements
• Lithium clearance is increased by caffeine; abrupt cessation can cause lithium toxicity
• Theophylline shares metabolic pathways; co-administration increases risk of toxicity for both compounds

Special Populations

• Pregnant women should limit intake to less than 200 mg daily (WHO/ACOG guidelines) due to associations with low birth weight and potential miscarriage risk
• Breastfeeding mothers should moderate intake, as caffeine passes into breast milk and may cause irritability in infants
• Children and adolescents should limit intake to 2.5 mg/kg body weight daily
• Elderly individuals may have slower caffeine metabolism and increased sensitivity to cardiovascular effects

Pharmacokinetic Profile